Literature DB >> 26618660

Introduction of a new Rotavirus vaccine: Initial results of uptake and impact on laboratory confirmed cases in Anglia and Essex, United Kingdom, July 2015.

Thomas Inns1, Amy Trindall2, Sara Dunling-Hall3, Ananda Giri Shankar4.   

Abstract

Rotavirus gastroenteritis accounts for an estimated 130,000 GP consultations and 13,000 hospitalisations for children under 5 y old each year in England and Wales. In July 2013, an oral live attenuated rotavirus vaccine (Rotarix®) was introduced into the UK infant immunisation program as a 2 dose schedule at 2 and 3 months of age. We collected vaccination uptake from October 2013 to March 2015 and laboratory confirmed cases data on children under the age of 5 y from 1 January 2004 to 31 May 2015. The vaccine uptake rates and laboratory confirmed cases were compared to provide evidence of the impact of this vaccination program. Vaccine uptake rates were available from sentinel data with between 91-98% of GP practices in Anglia and Essex providing data every month. These data showed from February 2014 to March 2015 between 90-92% of infants received the recommended 2 doses of Rotarix® each month. The numbers of rotavirus cases reported by laboratories decreased on average by 82% in the post vaccination seasons. The mean number of cases reported in weeks 1-22 for 2004-2013 in Anglia and Essex was 1,318. For the same period in 2014, 256 cases were reported and initial data for 2015 report 226 cases. In the first 5 months 2014 the greatest reduction in cases (89%) was seen in those under 1 yr (who would have been directly affected by vaccination) with case numbers falling to 59 from a mean 537 cases in the equivalent period for 2004-2013. Initially data suggests a 92% reduction in 2015 compared to the same pre-vaccination periods. For those aged 1 to <5 y who would not have been vaccinated, a reduction of 75% was also evident in 2014 and 77% in 2015, suggesting indirect protection in this group. In conclusion, initial results following the introduction of the Rotavirus vaccine clearly indicates a very good uptake of the vaccine and a significant reduction in the numbers of laboratory confirmed cases.

Entities:  

Keywords:  Rotarix; Rotavirus; Rotavirus vaccine; United Kingdom; immunisation

Mesh:

Substances:

Year:  2015        PMID: 26618660      PMCID: PMC4962965          DOI: 10.1080/21645515.2015.1108501

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  7 in total

1.  An estimate of the proportion of diarrhoeal disease episodes seen by general practitioners attributable to rotavirus in children under 5 y of age in England and Wales.

Authors:  T Djuretic; M Ramsay; N Gay; P Wall; M Ryan; D Fleming
Journal:  Acta Paediatr Suppl       Date:  1999-01

2.  Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease.

Authors:  J P Harris; M Jit; D Cooper; W J Edmunds
Journal:  Vaccine       Date:  2007-03-15       Impact factor: 3.641

3.  Exceptionally low rotavirus incidence in the Netherlands in 2013/14 in the absence of rotavirus vaccination.

Authors:  S Hahné; M Hooiveld; H Vennema; A van Ginkel; H de Melker; J Wallinga; W van Pelt; P Bruijning-Verhagen
Journal:  Euro Surveill       Date:  2014-10-30

4.  Reduction in rotavirus disease due to the infant immunisation programme in England; evidence from national surveillance.

Authors:  Christina Atchison; Sarah Collins; David Brown; Mary E Ramsay; Shamez Ladhani
Journal:  J Infect       Date:  2015-01-20       Impact factor: 6.072

5.  Assessing the Likely Impact of a Rotavirus Vaccination Program in England: The Contribution of Syndromic Surveillance.

Authors:  Zharain Bawa; Alex J Elliot; Roger A Morbey; Shamez Ladhani; Nigel A Cunliffe; Sarah J O'Brien; Martyn Regan; Gillian E Smith
Journal:  Clin Infect Dis       Date:  2015-03-31       Impact factor: 9.079

Review 6.  Vaccines for preventing rotavirus diarrhoea: vaccines in use.

Authors:  Karla Soares-Weiser; Harriet Maclehose; Hanna Bergman; Irit Ben-Aharon; Sukrti Nagpal; Elad Goldberg; Femi Pitan; Nigel Cunliffe
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

7.  Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study.

Authors:  T Vesikari; A Karvonen; R Prymula; V Schuster; J C Tejedor; R Cohen; F Meurice; H H Han; S Damaso; A Bouckenooghe
Journal:  Lancet       Date:  2007-11-24       Impact factor: 79.321

  7 in total
  3 in total

Review 1.  Effectiveness of the Oral Human Attenuated Rotavirus Vaccine: A Systematic Review and Meta-analysis-2006-2016.

Authors:  Corinne Willame; Marije Vonk Noordegraaf-Schouten; Emilia Gvozdenović; Katrin Kochems; Anouk Oordt-Speets; Nicolas Praet; Rosa van Hoorn; Dominique Rosillon
Journal:  Open Forum Infect Dis       Date:  2018-11-12       Impact factor: 3.835

2.  Estimating the Burden of Medically Attended Norovirus Gastroenteritis: Modeling Linked Primary Care and Hospitalization Datasets.

Authors:  Thomas Verstraeten; Tom Cattaert; John Harris; Ben Lopman; Clarence C Tam; Germano Ferreira
Journal:  J Infect Dis       Date:  2017-11-15       Impact factor: 5.226

3.  What proportion of care home outbreaks are caused by norovirus? An analysis of viral causes of gastroenteritis outbreaks in care homes, North East England, 2016-2018.

Authors:  Thomas Inns; Deb Wilson; Petra Manley; John P Harris; Sarah J O'Brien; Roberto Vivancos
Journal:  BMC Infect Dis       Date:  2019-12-31       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.